Compare IPI & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | IMMX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.0M | 306.2M |
| IPO Year | 2008 | 2021 |
| Metric | IPI | IMMX |
|---|---|---|
| Price | $32.28 | $6.03 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $24.00 | $12.00 |
| AVG Volume (30 Days) | 205.5K | ★ 1.0M |
| Earning Date | 03-02-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $222,728,000.00 | N/A |
| Revenue This Year | $23.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.93 | N/A |
| 52 Week Low | $20.86 | $1.34 |
| 52 Week High | $39.01 | $7.73 |
| Indicator | IPI | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 58.59 |
| Support Level | $32.10 | $5.73 |
| Resistance Level | $35.39 | $6.49 |
| Average True Range (ATR) | 1.72 | 0.48 |
| MACD | -0.25 | 0.09 |
| Stochastic Oscillator | 9.21 | 74.34 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, which is also the location of the firm's production facilities.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.